Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel

Harefuah

Volumn 147, Issue 3, 2008, Pages 211-215

  Berar Yanay, Noa ^a   Leshno, Moshe ^b   Hertzeanu, Lorette ^c   Weintrob, Naomi ^b  

^a HILLEL YAFFE MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Leumit Health Care Services   (Israel)

Author keywords

ACE inhibitors; Angiotensin II receptor blockers; Cost effectiveness; Diabetic nephropathy; Markov model

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; ECONOMICS; HUMAN; ISRAEL; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROBABILITY; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; ISRAEL; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 48949092263     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wild S, Roqlic G, Green A & al, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004; 27: 1047-53.
2. Th edition. Philadelphia: WB Saunders Company; 2004: 1731-74.
3. Hebrew source
4. United States Renal Data System. www.USRDS.org, accessed August 28, 2006.
5. Mitch WE, Treating diabetic nephropathy - are there only economic issues? N Engl J Med, 2004: 351; 1934-6.
6. Hsueh WA, Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting- inhibitors and angiotensin receptor antagonists. Current Opin Pharmacol, 2002; 2: 182-8.
7. Oikawa T, Freeman M, Lo W & al, Modulation of plasminogen activator inhibitor-I in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int, 1997; 51: 164-72.
8. Kagami S, Border WA, Miller DE & al, Angiotensin II stimulates extracellular matrix protein synthesis through induction of TGF β expression in rat glomerular mesangial cells. J Clin Invest, 1994; 93: 2431-7.
9. Lewis EJ, Hunsicker LG, Bain RP & al, The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med, 1993; 329: 1456-62.
10. American Diabetes Association. Recommendations for the treatment of diabetic nephropathy. Diabetes Care, 2006; 29 (Suppl 1): S21-3.
11. Ruggenenti P, Fassi A, Parvanova Ilieva A & al, Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 2004; 351: 1941-51.
12. Heart Outcomes Prevention Evaluation Study investigators. Effect of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet, 2000; 355: 253-9.
13. Barnett AH, Bain SC, Bouter P & al, Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med, 2004; 351: 1952-61.
14. Brener BM, Cooper ME, de Zeuw D & al, Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The RENAAL study investigators. N Engl J Med, 2001; 345: 861-9.
15. Lewis EJ, Hunsicker LG, Clarke WR & al, Renoprotective effect of the angiotensin receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001; 345: 851-60.
16. UK Prospective Diabetes Study Group. Efficacy of Atenolol and Captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J, 1998; 317: 713-20.
17. Palmer AJ, Tucker DMD, Valentine WJ & al, Cost-effectiveness of Irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant, 2005: 20; 1103-9.
18. Alexander CM, Lyle PA, Keane WF & al, Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Kidney Int, 2004; 66: S115-S117.
19. Palmer AJ & Rodby RA, Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. Kidney Int, 2004; 66: S118-S120
20. Palmer AJ, Annemans L, Roze S & al, Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Anti-hypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease. Diabetes Care, 2004; 27: 1897-1903.